Back to Africa Check

Antiviral medicine remdesivir not a Covid-19 vaccine, and distributed worldwide – not just in Africa

“Could the Corona experts explain why this vaccine is restricted to African countries only?” asks a message posted on Facebook in Kenya in January 2020. “As far as I know, we have only one Covid-19 affecting both Africa, EU, Canada and the US.”

The post includes two photos of a box of medicine. The first photo shows the front of the box, labelled: “Remdesivir for Injection 100 mg/vial”. Below is a notice: “Not for distribution in US, Canada, or EU.”

On the back of the box, in the second photo, is a notice: “For use in the below countries only.” It lists 47 countries, all in Africa.

The post has been viewed nearly 40,000 times so far.

Is remdesivir a Covid-19 vaccine? And is it only being distributed in African countries? We checked.


vaccine incorrect


Antiviral medicine, not vaccine

A vaccine stimulates the body’s immune system to produce antibodies against disease-causing germs such as viruses and bacteria. And remdesivir is not a Covid-19 vaccine.

It is instead an antiviral medication first developed to treat infection by a range of viruses, including the virus that causes hepatitis. Researchers found that the drug showed some efficacy against coronaviruses such as Middle East respiratory syndrome and severe acute respiratory syndrome.

The drug was also administered to a small number of patients as a treatment for Ebola but failed its first randomized clinical trial. 

In a 2020 randomised trial, researchers injected remdesivir into the veins of adult Covid-19 patients who had been hospitalised. The study included 1,064 patients, with remdesivir given to 541 of them and 521 given a placebo. Patients on remdesivir had a median recovery time of 10 days compared to 15 days for the patients on placebo. By day 15, the patients on remdesivir also had lower mortality rates and higher rates of clinical improvement. 

In October 2020 the US Food and Drug Administration approved remdesivir, under the brand name Veklury, for use in patients aged 12 and older for the treatment of Covid-19 serious enough to require hospitalisation.

“The approval of Veklury was supported by the agency’s analysis of data from three randomised, controlled clinical trials that included patients hospitalised with mild-to-severe Covid-19,” the FDA said

But the World Health Organization has since issued a conditional recommendation that remdesivir should not be used on hospitalised Covid-19 patients. “There is currently no evidence that remdesivir improves survival and other outcomes in these patients,” the WHO said.

Drug licensed for distribution worldwide – not just in Africa

Veklury was developed by pharmaceutical company Gilead. The company has signed voluntary licensing agreements for the drug with manufacturers in Egypt, India, and Pakistan. One of the manufacturers, Cipla, is an India-based pharmaceutical company. The company’s logo appears on the box shown in the Facebook post.

The Gilead website explains that the licensing agreements permit the manufacturers to produce the drug for distribution in 127 mostly lower and middle income countries. 

A full list of the countries is shown on their website. It includes the 47 African countries listed on the box in the Facebook post, as well as countries in Europe, Asia, and South America. The list excludes Canada, the US and the EU. 

But this doesn’t mean Gilead isn’t distributing Veklury in those countries. On 8 October 2020, the drug company signed a joint procurement agreement with the European Commission to distribute Veklury to EU member states. 

The US began stockpiling remdesivir in June 2020, reportedly buying up virtually all available stocks of the drug for the following three months. And Canada approved the drug for use in Covid-19 patients in August 2020, making the drug available through its public health system.

Remdesivir is not a Covid-19 vaccine and its distribution is not restricted to African countries. Drug company Cipla was granted licensing rights to distribute the drug in African countries but it is also available in the US, Canada and EU member states

Republish our content for free

We believe that everyone needs the facts.

You can republish the text of this article free of charge, both online and in print. However, we ask that you pay attention to these simple guidelines. In a nutshell:

1. Do not include images, as in most cases we do not own the copyright.

2. Please do not edit the article.

3. Make sure you credit "Africa Check" in the byline and don't forget to mention that the article was originally published on

For publishers: what to do if your post is rated false

A fact-checker has rated your Facebook or Instagram post as “false”, “altered”, “partly false” or “missing context”. This could have serious consequences. What do you do?

Click on our guide for the steps you should follow.

Publishers guide

Africa Check teams up with Facebook

Africa Check is a partner in Meta's third-party fact-checking programme to help stop the spread of false information on social media.

The content we rate as “false” will be downgraded on Facebook and Instagram. This means fewer people will see it.

You can also help identify false information on Facebook. This guide explains how.

Add new comment

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
limit: 600 characters

Want to keep reading our fact-checks?

We will never charge you for verified, reliable information. Help us keep it that way by supporting our work.

Become a newsletter subscriber

Support independent fact-checking in Africa.